Efficacy of Empagliflozin on cardiac function in non- diabetic patients after primary percutaneous angioplasty on left anterior descending coronary artery
Phase 2
- Conditions
- acute myocardial infarction.121-09
- Registration Number
- IRCT20200727048226N1
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
non-diabetic patients with PPCI on LAD that are SVD: non-diabetic patients definition: 1-HbA1C<6.5 2-history of non-diabetes 3-twice FBS<100 if two of three of these exist patient is eligible for entery of trial
Exclusion Criteria
1-History of serious hypersensitivity to empagliflozin or any component of the formulation; -Severe renal impairment (eGFR <30 mL/minute/1.73 m2), end-stage renal disease (ESRD), or dialysis 2-patients that have more than one vessel disease or have SVD with non-culprit lesion >70% or with SVD of LCX or RCA 3-patients 4- diabetic patients
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy of empagliflozin on cardiac function in non- diabetic patients admitted in Tehran Heart Center after primary PCI on LAD. Timepoint: echocardiography and blood sampling will be done 48 hours and after three months of reciveing medicine. Method of measurement: three dimentional echocardiography.
- Secondary Outcome Measures
Name Time Method